Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Empirical antifungal therapy.

Jean Klastersky1

  • 1Service de Médecine Interne et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1, rue Héger-Bordet, 1000 Bruxelles, Belgium. jean.klastersky@bordet.be

International Journal of Antimicrobial Agents
|March 12, 2004
PubMed
Summary

Fungal infections in cancer patients are rising, necessitating effective empirical therapies. Newer antifungals like voriconazole offer lower toxicity and better prevention of breakthrough infections compared to older agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron-deficiency anemia evaluation and treatment in hospitalized cancer patients: a feasibility study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Early and late code status documentation in cancer patients managed by a dedicated supportive care team.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Can febrile neutropenia re-invent its self?

Current opinion in oncology·2025
Same author

Evaluating pain management practices for cancer patients among health professionals in cancer and supportive/palliative care units: a Belgian survey.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2024
Same author

A meta-analysis on the risk of infection associated with intravenous iron therapy in cancer-associated anaemia: a double-edged sword?

Current opinion in oncology·2024
Same author

A new comprehensive and stratified concept for supportive care in cancer patients.

Current opinion in oncology·2024

Area of Science:

  • Mycology
  • Oncology
  • Infectious Diseases

Background:

  • Increasing incidence of invasive fungal infections (IFIs), especially in cancer patients.
  • Significant morbidity, mortality, and high costs associated with IFIs, particularly aspergillosis.
  • Empirical therapy is crucial due to delayed treatment correlating with worse outcomes.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of various empirical antifungal agents for febrile neutropenic patients.
  • To compare conventional amphotericin B with newer antifungal agents.
  • To assess the role of fluconazole, itraconazole, and voriconazole in empirical antifungal therapy.

Main Methods:

  • Comparative efficacy and toxicity analysis of antifungal agents.
  • Focus on persistent febrile neutropenia in cancer patients.

Related Experiment Videos

  • Review of clinical evidence for conventional amphotericin B, lipid formulations, fluconazole, itraconazole, and voriconazole.

    • Main Results:

    • Conventional amphotericin B shows comparable efficacy to newer agents but with higher toxicity.
    • Lipid formulations of amphotericin B offer similar efficacy with reduced toxicity but increased cost.
    • Fluconazole is effective if high-risk Aspergillus cases are excluded.
    • Itraconazole and voriconazole demonstrate equivalent efficacy to conventional and liposomal amphotericin B, respectively, with lower toxicity.
    • Voriconazole shows superior efficacy in preventing breakthrough fungal infections.

    Conclusions:

    • Empirical antifungal therapy is vital for managing febrile neutropenia in cancer patients.
    • Voriconazole presents a favorable option due to its efficacy, lower toxicity, and preventative capabilities against breakthrough infections.
    • Choice of agent should balance efficacy, toxicity, cost, and patient-specific risk factors.